Speaker Profile
PMWC LUMINARY AWARD
Transformed the precision oncology field through the development of the advanced non-invasive liquid biopsy
PhD, Chairman and Co-CEO, Guardant Health
Biography
Helmy Eltoukhy is a scientist and biotech entrepreneur with contributions to next-generation DNA sequencing and non-invasive liquid biopsy technologies. Eltoukhy is the co-founder and Chairman and co-CEO of Guardant Health (NASDAQ:GH). Under his leadership, Guardant Health launched the first comprehensive liquid biopsy for advanced stage cancer patients and the first blood-only liquid biopsy for recurrence monitoring for cancer survivors. The company also completed a 20,000-patient clinical study to validate a blood test for the early detection of colorectal cancer. Previously, he co-founded Avantome to commercialize semiconductor-based sequencing, which was later acquired by Illumina. He was named to Time Magazine's inaugural 50 Most Influential People in Healthcare, Fortune's 40 under 40, and in the 2021 list of the Top 50 Healthcare CEOs. He received his PhD, MS and BS degrees from Stanford University. He has co-authored high-impact publications spanning the sequencing and cancer fields and is a co-inventor on over 50 issued US patents.
Session Abstract – PMWC 2024 Silicon Valley
Track Chair: Laura J. van 't Veer, UCSF
- PMWC 2024 Award Ceremony
Pioneer Honoree: David Sidransky, Johns Hopkins
Pioneer Honoree: Helmy Eltoukhy
Pioneer Honoree: AmirAli Talasaz, Guardant Health - Utilities of Liquid Biopsy in Biomarker Testing
- Laura Vent Veer, UCSF - Status Quo of Clinical Liquid Biopsy (PANEL)
Chair: Helmy Eltoukhy, Guardant Health
- Sadakatsu Ikeda, Tokyo Medical University
- Heather Parsons, Dana-Farber Cancer Institute
- Sanjay Popat, The Royal Marsden - Liquid Biopsy for Health Monitoring and Disease Prevention (PANEL)
Chair: Anne-Renee Hartman, Adela Bio
- AmirAli Talasaz, Guardant Health
- Heather Parsons, Dana-Farber Cancer Institute
- Mary Pat Lancelotta, Adaptive Bio
- Sylvia Katina Plevritis, Stanford - Multi-Cancer Early Detection Through Multi-Biomarker Class Liquid Biopsy Testing (PANEL)
Chair: Tom Beer, Exact Sciences
- Wendy Rubinstein, National Cancer Institute
- Sheila D. Walcoff, Goldbug Strategies LLC - Keynote: Pioneering Liquid Nucleic Acids Tumor Fragments in Health and Diseases
- David Sidransky, Johns Hopkins - New Approaches in Liquid Biopsy (PANEL)
Chair: Victor Velculescu, Johns Hopkins
- David Sidransky, Johns Hopkins
- Dan Laudau, NY Genome Center
- Daniel De Carvalho, University of Toronto - Global Implications: A scalable Liquid Biopsy for HPV-related Cervical Cancer (PANEL)
Chair: Debra Fraser-Howze, D. Fraser Associates
- Belinda Nedjai, Wolfson Institute of Population Health
- Elisabeth Adams, Aquarius Population Health Limited - NCI Showcase
- Xiaohui Ni, Early Dx
- Daniel Kim, UCSC
